Brieflands

History

The company was first founded by Seyyed M. Miri and Seyed-M Alavian as an editorial group in a Medical Institute in 2007 to publish its medical journal. After three years of experience, the number of journals increased to 5 journals, and the company launched its first form of business as a VOF (collaboration) professional STM company in Heerlen, the Netherlands, which was called "Kowsarmedical Publishing." Respecting the publishing services (from submission to publishing), especially an in-house "Journal Management System," our journals increased to more than 60 STM journals between 2010 and 2019. Since 2022, "Brieflands" is the new brand name that acts as a "Science, Technical, Medical Publisher" that publishes more than 50 journals with the services provided by 97 expert employees in three different branches.

Business Profile

  • Brieflands is a Registered Trademark with record number 1454012.
  • Brieflands has been registered as a General partnership (Vennootschap onder firma) company in the Chamber of Commerce (Kamer van Koophandel) of the Netherlands since 2010.
  • Nedmedica is our related company which is specialized in Author Services. 
  • Our former branding name was Kowsarmedical Publishing (2010-2021).
 

Communities in Brieflands

Select a community to browse its collections.

Recent Submissions

Thumbnail Image
Item
Full Characterization of Respiratory Syncytial Virus Pediatric Admissions Before and During the COVID-19 Pandemic: A 5-year Study
(Brieflands, 2025-06-11) Rosa Amorim-Figueiredo; Raquel da Costa Neves; Joao Simoes; Margarida Simao; Rui Domingues; Ana Paula Rocha; Sara Tavares Ferreira; Rosario Perry da Camara; Beatriz Costa; Rita Machado; Diana Amaral; Rosa Amorim-Figueiredo [0000-0001-6442-1769]; Raquel da Costa Neves [0009-0003-8670-2002]; Joao Simoes [0000-0001-5193-5699]; Margarida Simao [0009-0009-3246-8066]; Rui Domingues [0000-0001-9427-3939]; Ana Paula Rocha [0000-0001-6594-4772]; Sara Tavares Ferreira [0000-0001-8295-6724]; Rosario Perry da Camara [0009-0007-4304-5267]; Beatriz Costa [0009-0002-2473-2030]; Rita Machado [0000-0002-6614-5355]; Diana Amaral [0009-0009-3210-3542]
Background: It was unknown if respiratory syncytial virus (RSV) severity changed during the COVID-19 pandemic, as previous studies presented conflicting results. It is important to understand if RSV severity is affected by viral pandemics to determine the choice of the most suitable RSV prophylactic measures. Objectives: The full characterization of the pediatric RSV hospitalized population before and during the COVID-19 pandemic, searching for changes in RSV severity. Risk factors for severe RSV disease were also analyzed. Methods: A retrospective cohort study of the RSV patients admitted to a tertiary pediatric hospital between January 2017 and March 2022. The primary outcome was the need for high-flow (HF) oxygen therapy before and during the COVID-19 pandemic. Other analyzed data included age, gender, prematurity, comorbidities, reason for admission, viral coinfections, bacterial superinfection, low-flow oxygen, non-invasive and mechanical ventilation (MV), admission to the pediatric intensive care unit (PICU), and length of stay. Results: During the COVID-19 pandemic, a slight increase in severity was observed, as the need for HF increased (P = 0.001, adjusted-P = 0.008). There was also an increase in the proportion of RSV hospitalized patients aged 24 months or older (P = 0.002, adjusted-P = 0.015). There were no differences regarding the length of stay, gender, prematurity, chronic disease, reasons for admission, bacterial superinfection, viral coinfections, admission to the PICU, low-flow oxygen therapy, non-invasive ventilation (NIV), or MV. Conclusions: Our study clarified the impact of the COVID-19 pandemic on RSV severity and found an age shift in the RSV burden during the pandemic. We concluded that RSV severity may have been affected by the COVID-19 pandemic. Since RSV severity changes with viral pandemics, it is important to continue monitoring RSV epidemiology to choose the best RSV prophylactic method, such as palivizumab or nirsevimab for infants and the RSV vaccine for pregnant women, considering the birth date of the baby, RSV seasonality, and RSV severity of that season.
Thumbnail Image
Item
The Effect of Zinc Supplementation on Relapse of Anxiety and Depression in Opioid-Dependent Patients Treated with Methadone
(Brieflands, 2025-06-30) Amirali Moghadam Sadegh; Shahin Norouzi; Neda Sadrizadeh Irani; Seyed Esmail Mousavi Asl; Simin Ghaffari Kalaf Mohammadi; Amirali Moghadam Sadegh [0000-0001-6772-0449]; Neda Sadrizadeh Irani [0000-0003-4694-7809]
Background: The human body contains 2 to 3 mg of zinc, with the highest concentrations found in the hippocampus, amygdala, and frontal cortex, which are associated with emotions. Additionally, studies have shown that taking zinc supplements improves mood in individuals undergoing antidepressant treatment as well as in the general population. Objectives: The present study aimed to evaluate the efficacy of zinc supplementation in reducing the likelihood of anxiety and depression relapse in opioid-dependent patients undergoing methadone maintenance treatment. Patients and Methods: A descriptive cross-sectional study was conducted on opioid-dependent patients undergoing methadone treatment. Participants were divided into groups based on the random block permutation method: The case group [treated with zinc supplements for 3 months (n = 32)] and the control group [treated with a placebo for 3 months (n = 31)]. Inclusion criteria included receiving methadone maintenance therapy (MMT), absence of major neurological and underlying diseases, and absence of medications that reduce serum zinc levels. Exclusion criteria included a history of allergy to zinc-containing compounds and taking zinc supplements before the intervention. The measurement tools included a demographic questionnaire and Beck’s Anxiety and Depression Inventory. Data were analyzed using SPSS version 26, with a P-value of < 0.05 deemed statistically significant. Results: In the case group, a significant improvement in quality of life, specifically in physical health, mental health (MH), and social health, was observed compared to the control group after zinc supplementation (P < 0.05). After three months of zinc supplementation, anxiety, stress, and depression levels significantly decreased in the case group compared to the control group (P < 0.05). Conclusions: Zinc supplementation significantly helped reduce anxiety and depression symptoms in patients receiving methadone maintenance treatment.
Thumbnail Image
Item
Measles Resurgence in Iran: A Preventable Public Health Crisis
(Brieflands, 2025-06-30) Masoud Mardani; Amirreza Keyvanfar; Sayna Mardani; Masoud Mardani [0000-0001-6082-072X]; Amirreza Keyvanfar [0000-0003-2278-5390]
This article does not have an abstract.
Thumbnail Image
Item
The Effectiveness of Psychosocial Intervention on Internalized Stigma and Quality of Life in Parents of Children with Autism Spectrum Disorder
(Brieflands, 2025-08-31) Fatemeh Ghofrani-Disfani; Masoume Pourmohamadreza-Tajrishi; Mohsen Vahedi; Fatemeh Ghofrani-Disfani [0009-0005-8249-5098]; Masoume Pourmohamadreza-Tajrishi [0000-0001-9445-4748]; Mohsen Vahedi [0000-0002-4645-6770]
Background: Improving parental awareness and skills regarding autism spectrum disorder (ASD) can ease caregiving challenges and mitigate stigma-related stress in mothers. Objectives: This study aimed to evaluate the effectiveness of a psychosocial intervention on internalized stigma and quality of life among parents of children with autism. Methods: This quasi-experimental study utilized a pre-test and post-test design with a control group and a two-month follow-up. Targeting parents of children with ASD in Tehran, diagnosed at least four years prior, 30 parents were conveniently sampled and randomly matched by child age into experimental and control groups. The sample size was estimated based on previous studies and statistical power calculations, resulting in 15 participants per group. Parents aged 25 - 50, children aged 3 - 12 with a confirmed autism diagnosis at least four years prior, and willingness to participate were eligible criteria. Participants were excluded if they missed more than two sessions or had recent involvement in similar programs within the past six months. The experimental group underwent 10 psychosocial intervention sessions, while the control group received only necessary rehabilitative services. Assessments were conducted using the World Health Organization Quality of Life Scale (WHOQOL-100) and an Internalized Stigma Questionnaire (ISQ) at three intervals, with data analyzed using SPSS version 25 through analysis of covariance (ANCOVA) and repeated measures ANOVA. Results: Participants averaged 40.3 ± 9.85 years, with no significant age differences between groups, and their children’s mean age was 10.17 years. The ANCOVA revealed significant improvements in internalized stigma and overall quality of life in the experimental group post-intervention, with 27% and 23% of variance explained, respectively. Effect sizes indicated that participation accounted for 23%, 16%, and 43% of the variance in psychological health, social relationships, and environment domains. Repeated measures ANOVA confirmed significant group and time effects on internalized stigma and quality of life, with 61% and 12% of variance attributable to the intervention. Only the social relationships subscale showed significant differences (P < 0.05), explaining 15% of its variance; other subscales showed no significant change. Other subscales, including physical health, psychological health, and environment, did not exhibit significant differences (P > 0.05). Conclusions: The psychosocial intervention program significantly improves stigma perception and quality of life for parents of children with ASD, offering strategies to cope with autism-related challenges effectively.
Thumbnail Image
Item
Pharmacist Interventions and Drug-Related Problems in CVD Patients: An ECPIS-Based Study
(Brieflands, 2025-07-31) Farah A. Kareem; Mohammed Y. Jamal; Farah A. Kareem [0009-0001-8934-0065]; Mohammed Y. Jamal [0000-0003-0878-8384]
Background: Cardiovascular diseases (CVDs) are rapidly becoming an alarming and more common reason for morbidity and mortality. Drug-related problems (DRPs) are more common among hospitalized patients, and they can increase patient morbidity and mortality. Objectives: The present study aimed to investigate the effect of pharmacist interventions on DRPs using the Electronic Clinical Pharmacists Intervention Sheet (ECPIS) in patients with CVDs. Methods: A prospective study conducted in Iraq - Baghdad at Ibn-AL-Bitar Center for Cardiac Surgery, in 2024 for 5 months (from January to May), used the ECPIS. The hospital pharmacists who participated in this study were 10 out of 30 pharmacists who worked in the three internal cardiology wards. The pharmacists' hospital screened the files of patients from the first day of admission and follow-up until discharge. They reviewed patients' medication to identify DRPs and medication errors, and the classification of DRPs was conducted by the ECPIS, which is implemented in all Iraqi hospitals. They also documented the interventions made by pharmacists to address these problems. Results: The total number of drugs that caused problems detected by the pharmacists was 187. Proton pump inhibitors were the most frequent drugs found (16.6%), followed by heparin (14.4%), and antibiotics (11.8%). A total of 175 problems were detected, with adverse drug reactions (ADRs) being the most common problem detected (52.6%). The acceptance of interventions provided by the pharmacists to the physicians was 82.9%, while the not accepted interventions were 17.1%. Conclusions: This study highlights the importance of pharmacist involvement in identifying and preventing DRPs in patients with CVDs. Pharmacist interventions were frequently successful, demonstrating their role in improving patient safety.